IO Learning Webinar - The TARGET Study

The TARGET Study is a global real-world study set across eight countries that confirms TheraSphere™ as safe and effective treatment for HCC, demonstrating reproducible clinical outcomes across a broad patient population. Hear from Professor Marnix Lam and Dr. Riad Salem, two of the global PIs, as they discuss the trial design, outcomes, and implications to Y-90 treatment practices.

Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world.

PI-1013708-AA